These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38842787)

  • 1. Anthracycline-Induced Cardiomyopathy in Cancer Survivors: Management and Long-Term Implications.
    Mohsenizadeh SA; Rajaeinejad M; Khoshfetrat M; Arefizadeh R; Mousavi SH; Mosaed R; Kazemi-Galougahi MH; Jalaeikhoo H; Faridfar A; Nikandish M; Alavi-Moghadam S; Arjmand B
    Adv Exp Med Biol; 2024 Jun; ():. PubMed ID: 38842787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease in survivors of childhood cancer.
    Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
    Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study.
    Skitch A; Mital S; Mertens L; Liu P; Kantor P; Grosse-Wortmann L; Manlhiot C; Greenberg M; Nathan PC
    BMC Cancer; 2017 Aug; 17(1):519. PubMed ID: 28774277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?
    Basar EZ; Corapcioglu F; Babaoglu K; Anik Y; Gorur Daglioz G; Dedeoglu R
    Pediatr Hematol Oncol; 2014 Apr; 31(3):237-52. PubMed ID: 24499452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
    Rygiel K
    Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Chung WB; Youn HJ
    Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational and design of SATRACD study: detecting subclinical anthracycline therapy related cardiac dysfunction in low income country.
    Zhang W; Azibani F; Okello E; Kayima J; Walusansa V; Orem J; Sliwa K
    Afr Health Sci; 2021 Jun; 21(2):647-654. PubMed ID: 34795719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of anthracycline cardiotoxicity in children and adults.
    Grenier MA; Lipshultz SE
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Laursen AH; Thune JJ; Hutchings M; Hasbak P; Kjaer A; Elming MB; Ripa RS
    Clin Physiol Funct Imaging; 2018 Mar; 38(2):176-185. PubMed ID: 28251781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
    Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
    Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac toxicity after anthracycline chemotherapy in childhood.
    Iarussi D; Indolfi P; Galderisi M; Bossone E
    Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline-associated cardiotoxicity in survivors of childhood cancer.
    Trachtenberg BH; Landy DC; Franco VI; Henkel JM; Pearson EJ; Miller TL; Lipshultz SE
    Pediatr Cardiol; 2011 Mar; 32(3):342-53. PubMed ID: 21221562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular Mechanisms Mediating Exercise-Induced Protection against Cardiotoxic Anthracycline Cancer Therapy.
    Dozic S; Howden EJ; Bell JR; Mellor KM; Delbridge LMD; Weeks KL
    Cells; 2023 May; 12(9):. PubMed ID: 37174712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
    Riccio G; Coppola C; Piscopo G; Capasso I; Maurea C; Esposito E; De Lorenzo C; Maurea N
    Hum Vaccin Immunother; 2016 May; 12(5):1124-31. PubMed ID: 26836985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.